Barclays PLC Equillium, Inc. Transaction History

Barclays PLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$3.77 - $6.99 $56 - $104	-15 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$5.11 - $7.64 $76 - $114	15 New	15 $0
Q4 2020 Feb 11, 2021	SELL	$3.48 - $6.58 $348 - $658	-100 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$2.78 - $26.5 $278 - $2,650	100 New	100 $1,000
Q3 2019 Nov 14, 2019	SELL	$3.31 - $5.6 $317 - $537	-96 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$5.28 - $8.2 $7,281 - $11,307	-1,379 Reduced 93.49%	96 $1,000
Q1 2019 May 15, 2019	BUY	$5.84 - $12.02 $7,738 - $15,926	1,325 Added 883.33%	1,475 $12,000
Q4 2018 Feb 14, 2019	BUY	$6.32 - $19.44 $948 - $2,916	150 New	150 $1,000

11.5M

38.1K

Ticker EQ
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,352,100
Market Cap $47.1M
Description
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which i...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.